This report provides key findings from the 2022 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment among the noninstitutionalized U.S. population aged 12 or older. Estimates are presented by age group and by race/ethnicity for selected measures.

Read key findings from the 2021 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment. Metrics in the report cover the civilian, noninstitutionalized US population ages 12 and older. Estimates are presented by age group and by race/ethnicity for selected measures. Unlike other NSDUH Annual National Reports, the 2021 report has no discussion of trends over time, because changes in survey methodology mean the indicators are not comparable to past NSDUH estimates.

This guide offers information and tips to disaster responders and first responders to help them manage stress during crisis response. It describes how stress affects the body and suggests ways for individuals and organizations to promote and engage in stress management.

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

This brochure features the national Disaster Distress Helpline, which supports people who are coping with the after effects of a disaster. Learn about a disasters’ potential to cause psychological stress, warning signs of distress, and tips for coping.

This wallet-size card includes the national Disaster Distress Helpline and lists warning signs of distress. It encourages those experiencing signs of psychological stress to call or text the helpline for support.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.